What it is
Two different things are sold or discussed under this name, and they are often mixed up. Thymosin beta-4 is a natural protein made of 43 amino acids (the building blocks of proteins). It is found in almost every human cell and in body fluids such as blood, tears and wound fluid. "TB-500" is a trade name, not an official drug name. When anti-doping laboratories analysed TB-500 products in 2012, the active ingredient they found was not the full protein. It was a short piece of it: seven amino acids (positions 17 to 23, written LKKTETQ) with a small chemical cap called an acetyl group added to the front end.
More on what it is and where it came from
The name is not used consistently. The US Food and Drug Administration (FDA) wrote in 2026 that it has seen different substances, including different salts and different active molecules, sold under the same name TB-500, and that many websites call TB-500 a synthetic version of thymosin beta-4 and use the two names as if they meant the same thing. FDA states plainly that thymosin beta-4 and TB-500 are not the same substance. A 2025 doping-control paper likewise noted online products claiming to contain either the short capped fragment or thymosin beta-4 itself. A vial labelled TB-500 may therefore hold the 7-amino-acid fragment, the full 43-amino-acid protein, or something else. Only a lab test can tell.
This matters because the evidence does not transfer from one to the other. Almost all animal research and every completed human trial used full-length thymosin beta-4, mostly as eye drops or a skin gel. FDA's 2026 review found no study in which the TB-500 fragment had been given to people. Neither substance is an approved medicine.
Thymosin beta-4 was isolated from calf thymus and its 43-amino-acid sequence was published in 1981 by Low, Hu and Goldstein. In 1991 Safer and colleagues showed it was identical to a protein in human platelets that holds on to actin, a main building material of the cell's inner skeleton. Researchers at the US National Institutes of Health reported in 1999 that it sped up skin wound healing in rats. RegeneRx Biopharmaceuticals later sponsored human trials of a thymosin beta-4 skin gel, and ReGenTree sponsored trials of thymosin beta-4 eye drops (RGN-259). According to FDA's 2026 review, the 7-amino-acid fragment was first made in 2003 for a mouse wound study, and a veterinary product called TB-500 appeared around 2011, marketed for racehorses and greyhounds. In 2012 doping-control laboratories in Ghent and Hong Kong published the chemical identity of what TB-500 products contained.
How it is thought to work
Inside cells, thymosin beta-4 binds single units of actin and holds them in reserve. Lab work from 1991 showed it pairs one-to-one with actin units and stops them joining into filaments. Because cells rebuild their actin skeleton in order to move, researchers think this is one reason thymosin beta-4 affects cell migration (cells moving into a wound).
More on how it works
In rat and mouse studies, thymosin beta-4 applied to wounds appeared to speed up skin closure, increase collagen and new blood vessel growth, and reduce inflammation in injured corneas (the clear front of the eye). A 2010 review described several active regions in the protein. The stretch LKKTETQ, the actin-binding region, was linked in lab and animal work to blood vessel growth, wound healing and cell migration. Other effects were linked to different parts of the protein that the TB-500 fragment does not contain.
It is not established that the capped fragment sold as TB-500 behaves like the full protein. FDA noted that the 2003 mouse study used the fragment without the acetyl cap, and that adding the cap can change how a peptide behaves. In a 2024 cell study, TB-500 itself did not close a scratch wound in a dish of skin cells faster than no treatment, while one of its breakdown products did.
What is established in people
No published human trial of the TB-500 fragment was found, and FDA's May 2026 review reported finding no study in which it had been given to people. One trial of the fragment is listed on ClinicalTrials.gov (NCT07487363, first posted March 2026, 80 participants planned, one site in China) with no results; its record contains unusual wording and should be treated with caution. Full-length thymosin beta-4 has been tested in people: two small safety studies of injections in healthy volunteers (40 and 84 people, up to 14 days), three phase 2 skin-gel trials in which healing rates were no better than placebo, and eye-drop trials in which the largest dry-eye studies (601 and 700 people) showed near-identical results for drug and placebo and a small phase 3 corneal-healing trial (18 people) showed a non-significant trend. A 2025 randomised, placebo-controlled trial of full-length thymosin beta-4 in 96 heart-attack patients found no overall difference in the area of dead heart muscle at 90 days; a smaller area in the 43 patients first treated within 8 hours is a subgroup result that needs confirming. No thymosin beta-4 product has been approved, and nothing in people supports the tendon, muscle or joint claims made for TB-500.
What the studies found
19 studies, human trials first. Each links to the paper or registry record.
- Human trial2025
Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.
In mice, a week of treatment after a heart attack prevented loss of heart function and scarring at 28 days, and lowered a blood marker of heart strain.
Full finding, who was studied, and limits
Who: Tested full-length thymosin beta-4 made by genetic engineering (recombinant, sponsor's code NL005), not the TB-500 fragment. Mice with induced heart attacks, heart cells in dishes, and a randomised, placebo-controlled, double-blind phase 2b trial in 96 patients in China who had a major heart attack (STEMI) treated by opening the blocked artery with a stent. Run from Fuwai Hospital, Beijing, with 13 hospitals; three authors worked for Beijing Northland Biotech, the company developing the drug. Trial registered as NCT05984134.
In mice, a week of treatment after a heart attack prevented loss of heart function and scarring at 28 days, and lowered a blood marker of heart strain. In the trial, across all 96 patients there was no significant difference in infarct size (the area of dead heart muscle) between thymosin beta-4 and placebo at 90 days. In a subgroup of 43 patients who got their first dose within 8 hours of the stent procedure, infarct size was significantly smaller than with placebo. Another early measure of damaged small vessels showed a trend that did not reach significance (p = 0.06), and the main pumping-strength measure (ejection fraction) did not differ from placebo.
Read with care: The trial's overall result was negative; the positive finding comes from a subgroup, which is weaker evidence and needs confirming. Company employees were among the authors. The registry lists 90 enrolled while the paper reports 96, and the registry had no posted results when checked. Safety results from the trial were not read. It used the full protein given in hospital, so it says nothing about the 7-amino-acid TB-500 fragment.
- Human trial2022
Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy: SEER-1
Complete healing at 4 weeks occurred in 6 of 10 patients on RGN-259 and 1 of 8 on placebo (p = 0.0656, which did not reach the usual threshold for statistical significance).
Full finding, who was studied, and limits
Who: 18 patients with neurotrophic keratopathy (a rare condition in which a nerve-damaged cornea fails to heal): 10 received thymosin beta-4 eye drops (RGN-259) and 8 received placebo drops for 4 weeks.
Complete healing at 4 weeks occurred in 6 of 10 patients on RGN-259 and 1 of 8 on placebo (p = 0.0656, which did not reach the usual threshold for statistical significance). Comfort scores improved more with the drug. The authors reported no significant adverse effects.
Read with care: Very small. The registry lists the trial as terminated for a 'business decision'. The main result was a trend, not a statistically significant finding. A 2025 Cochrane review rated the evidence from this trial as low certainty. Several authors worked for the developer. A second trial, SEER-2 (NCT05555589, 70 patients), is listed as completed in July 2026 with no results posted as of November 2026.
- Human trial2020
A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye (ARISE-3)
On the two main goals, the posted results were almost identical between groups.
Full finding, who was studied, and limits
Who: 700 people with dry eye enrolled at multiple centres; 351 started thymosin beta-4 eye drops (RGN-259) and 348 started placebo drops, for 14 days. This is the largest human trial of thymosin beta-4 found.
On the two main goals, the posted results were almost identical between groups. Change in lower-cornea staining was -0.41 with RGN-259 and -0.46 with placebo. Change in eye discomfort was -0.4 in both groups. No serious adverse events were recorded in either group. Other adverse events were recorded in 47 of 350 people on RGN-259 (13%) and 31 of 349 on placebo (9%).
Read with care: Phase 3 and well sized, but it did not show a benefit on its main measures. The registry posts averages without a statistical test. The earlier ARISE-2 trial (NCT02974907, 601 people, 28 days) also posted near-identical changes on its two main measures. Eye drops of the full protein tell us nothing about the injected TB-500 fragment.
ClinicalTrials.gov NCT03937882 (ReGenTree, LLC) · clinicaltrials.gov
- Human trial2015
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.
Neither of the two main goals (eye discomfort and staining of the lower cornea at day 29) showed a significant difference between drug and placebo.
Full finding, who was studied, and limits
Who: 72 people with moderate to severe dry eye at one centre, randomised 1:1 to full-length thymosin beta-4 eye drops (RGN-259) or placebo drops for 28 days.
Neither of the two main goals (eye discomfort and staining of the lower cornea at day 29) showed a significant difference between drug and placebo. Some secondary measures favoured the drug, including a 27% lower discomfort score during a dry-air challenge on day 28 (P=0.0244). No adverse events were reported.
Read with care: The trial missed both primary endpoints. The authors' conclusion that it 'confirms the efficacy' rests on secondary measures, which are weaker evidence. One author worked for the contract research company that ran the trial.
- Human trial2010
A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.
Side effects were infrequent and mild or moderate.
Full finding, who was studied, and limits
Who: 40 healthy volunteers in four groups of 10, given synthetic full-length thymosin beta-4 or placebo into a vein, once and then daily for 14 days.
Side effects were infrequent and mild or moderate. There were no serious adverse events and no dose-limiting toxicity over 14 days.
Read with care: Small, short, healthy volunteers, full-length protein given in a clinic. It was a safety study, not a test of benefit. It does not cover the TB-500 fragment, long-term use or unregulated products. The follow-on heart trial registered by the same sponsor (NCT01311518) was withdrawn before enrolling anyone.
Annals of the New York Academy of Sciences · pubmed.ncbi.nlm.nih.gov
- Human trial2010
The effect of thymosin treatment of venous ulcers.
Safety was judged acceptable and similar to placebo.
Full finding, who was studied, and limits
Who: Patients with venous leg ulcers at eight sites in Italy and Poland, randomised to a full-length thymosin beta-4 skin gel at one of three strengths or to placebo gel for up to 84 days. The paper reports 73 patients; the registry reports 72 (55 on thymosin beta-4, 17 on placebo).
Safety was judged acceptable and similar to placebo. The paper says one strength 'may have the potential' to speed healing and that about 25% of patients healed completely within 3 months. The registry results show complete healing in 12 of 55 patients on thymosin beta-4 (22%) and 4 of 17 on placebo (24%).
Read with care: Phase 2, small groups, safety was the main goal. The share of patients who healed was about the same with drug and placebo. A sister trial in pressure ulcers (NCT00382174, 72 patients) showed the same pattern: 8 of 54 healed on thymosin beta-4 and 3 of 18 on placebo. A later review (Treadwell 2012), whose authors include an investigator from this trial, argued healing was faster by almost a month among those patients who did heal.
- Human trial2010
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
The trial was stopped early.
Full finding, who was studied, and limits
Who: 30 patients with epidermolysis bullosa, a rare inherited skin-blistering disease: 22 received full-length thymosin beta-4 gel and 8 received placebo gel for up to 56 days.
The trial was stopped early. The registry gives the reason as lack of available patients and expiry of the study drug. Wounds healed by day 56 in 8 of 22 patients on thymosin beta-4 and 5 of 8 on placebo, a difference that was not statistically significant. One non-serious adverse event was recorded in the thymosin beta-4 group and no serious ones.
Read with care: Very small, stopped early, and the placebo group did at least as well. It does not show a benefit. A later trial of the gel in this disease (NCT03578029) was also terminated, after enrolling 4 patients.
- Animal study2026
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
At four weeks, the repaired tendons in the TB-500 group took more force before breaking than untreated tendons: a middle value of 37.4 newtons versus 26.9 newtons (p = 0.04 after correction for multiple comparisons).
Full finding, who was studied, and limits
Who: 32 young healthy male rats whose Achilles tendon (the tendon at the back of the ankle) was cut and stitched back together, in four groups of 8: no treatment, BPC-157, TB-500, or both, given for four weeks. Strength was tested on 4 tendons per group. Run by an orthopaedic team in Istanbul, Turkey; the authors reported no funding and no conflicts of interest.
At four weeks, the repaired tendons in the TB-500 group took more force before breaking than untreated tendons: a middle value of 37.4 newtons versus 26.9 newtons (p = 0.04 after correction for multiple comparisons). This was the only group that differed significantly on strength; BPC-157 alone (37.2 newtons) and the combination (34.5 newtons) did not. Under the microscope, the TB-500 group's tendon tissue also scored as more orderly than controls. Combining the two peptides gave no extra benefit.
Read with care: Rats, not people, and a single four-week time point. Only 4 tendons per group were strength-tested, and no sample-size calculation was done. Only breaking force was measured; tendon thickness and stiffness were not. The 'TB-500' was bought from a commercial peptide supplier, described only as a synthetic peptide derived from thymosin beta-4, and the paper does not report its sequence or any test of what the vials contained, so it is not certain whether it was the 7-amino-acid fragment or something else. The authors themselves call the results hypothesis-generating rather than confirmatory. This is the only tendon or ligament study found that used a product sold as TB-500; a 2013 rat knee-ligament study (PMID 23523891) used the full thymosin beta-4 protein instead.
Joint Diseases and Related Surgery · pubmed.ncbi.nlm.nih.gov
- Animal study2026
Thymosin β4 increases hepatic susceptibility to repeated irradiation and enhances cellular senescence and fibrosis.
After repeated radiation, the mice making extra thymosin beta-4 survived markedly less well, lost more body and liver weight, and stored more fat in the liver than normal mice.
Full finding, who was studied, and limits
Who: Mice genetically engineered to make extra full-length thymosin beta-4 throughout life (transgenic), compared with normal mice, all given radiation to the body once a week for five weeks. Group sizes are not given in the abstract. Pusan National University, South Korea.
After repeated radiation, the mice making extra thymosin beta-4 survived markedly less well, lost more body and liver weight, and stored more fat in the liver than normal mice. Standard blood tests of liver damage were not higher, but their livers showed more signs of cellular ageing (senescence proteins p21, p53 and p16), more activation of scar-forming liver cells and more collagen (scar tissue). The authors concluded that raised thymosin beta-4 may make the liver more vulnerable to repeated radiation.
Read with care: Mice that made extra protein all their lives; thymosin beta-4 and TB-500 were not given as a treatment. Group sizes not stated. Published online ahead of print. It is one study and shows a possible downside in a specific setting, not a finding in people.
- Animal study2025
Alkaline Phosphatase-Triggered Spatiotemporal Repair of Corneal Injury with TB500 Peptide Hydrogel.
In dishes, the gel helped human corneal surface cells move, multiply and rebuild the seals between them.
Full finding, who was studied, and limits
Who: Tested the TB-500 fragment sequence (LKKTETQ), but built into a new gel-forming molecule (a precursor called Nap-YpYY-TB500), not plain TB-500. Human cornea cells in dishes and animals with chemical (alkali) burns to the cornea; the species and group sizes are not given in the abstract. Eye and pharmacy researchers at Nankai and Yantai Universities, China.
In dishes, the gel helped human corneal surface cells move, multiply and rebuild the seals between them. In the alkali-burn model, the gel significantly sped up regrowth of the corneal surface, reduced inflammation and improved the cornea's barrier function. The authors describe it as the first use of TB-500 in the eye.
Read with care: The fragment was chemically attached to a gel-forming chain, so results may not apply to the TB-500 fragment on its own. Animal species, numbers and length of follow-up are not stated in the abstract. It is an eye-surface study, not a test of tendon or muscle repair or of injected TB-500.
ACS Applied Materials & Interfaces · pubmed.ncbi.nlm.nih.gov
- Animal study2012
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.
The authors stated that the key ingredient of TB-500 was the peptide LKKTETQ with an artificial acetyl cap on its front end.
Full finding, who was studied, and limits
Who: Horses given a single administration of a veterinary TB-500 preparation; the abstract does not give the number of horses. Hong Kong Jockey Club racing laboratory.
The authors stated that the key ingredient of TB-500 was the peptide LKKTETQ with an artificial acetyl cap on its front end. They detected the peptide and its breakdown products in horse blood and urine after administration, down to 0.02 ng/mL in plasma and 0.01 ng/mL in urine.
Read with care: A detection study for doping control in horses. It did not measure any healing effect or safety outcome.
- Animal study2012
Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes.
Treatment after the heart attack thickened the heart's outer layer and increased small blood vessel density.
Full finding, who was studied, and limits
Who: Genetically marked mice given full-length thymosin beta-4 after an induced heart attack.
Treatment after the heart attack thickened the heart's outer layer and increased small blood vessel density. But cells from that outer layer did not turn into new heart muscle cells, and did not become blood vessel lining cells inside the heart muscle. The authors said this gave reason for caution about clinical hopes.
Read with care: Mice. It tests one proposed mechanism, not overall heart function. It tempers earlier reports that thymosin beta-4 could prompt the heart to make new muscle.
Journal of Molecular and Cellular Cardiology · pubmed.ncbi.nlm.nih.gov
- Animal study2004
Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.
Thymosin beta-4 promoted movement and survival of heart cells in culture.
Full finding, who was studied, and limits
Who: Mouse heart cells in culture and mice with a tied-off coronary artery (an induced heart attack), treated with full-length thymosin beta-4; group sizes are not given in the abstract.
Thymosin beta-4 promoted movement and survival of heart cells in culture. In mice after an induced heart attack, treatment was associated with better early survival of heart muscle cells and improved heart function.
Read with care: Mice and full-length protein. See the next entry for a later study that did not confirm one of the more striking heart-repair claims.
- Animal study2003
Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice.
Full-length thymosin beta-4 improved wound contraction and collagen in diabetic mice and sped up healing in aged mice.
Full finding, who was studied, and limits
Who: Diabetic mice and 26-month-old (aged) mice with skin wounds; group sizes are not given in the abstract.
Full-length thymosin beta-4 improved wound contraction and collagen in diabetic mice and sped up healing in aged mice. A 7-amino-acid peptide, LKKTETQ, promoted repair in the aged mice to a degree comparable to the full protein. This is the study most often cited for the fragment.
Read with care: FDA's 2026 review notes the peptide tested here did not carry the acetyl cap that TB-500 has, was applied to the wound surface, and was tested without a dose-response comparison. FDA says its results cannot be directly carried over to TB-500.
- Animal study2003
Role of thymosin beta4 in tumor metastasis and angiogenesis.
Tumours from cells making extra thymosin beta-4 were larger at 20 days (21.7 mm versus 13.3 mm).
Full finding, who was studied, and limits
Who: Mouse melanoma (skin cancer) cells engineered to make extra thymosin beta-4, injected into mice (20 mice in the lung-spread experiment).
Tumours from cells making extra thymosin beta-4 were larger at 20 days (21.7 mm versus 13.3 mm). Mice had more tumour nodules in the lungs (46.7 versus 10.9 on average), and tumours had 4.4 times more blood vessels. The authors concluded thymosin beta-4 may promote cancer spread by stimulating cell movement and blood vessel growth.
Read with care: This is a theoretical concern, not a finding in people. The cancer cells themselves were made to overproduce the protein; the study did not give thymosin beta-4 or TB-500 as a treatment. No human study has shown that either causes or worsens cancer, and none has ruled it out.
Journal of the National Cancer Institute · pubmed.ncbi.nlm.nih.gov
- Animal study2002
Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury.
Treated corneas regrew their surface layer faster at every time point and had fewer inflammatory white blood cells at 7 days than controls.
Full finding, who was studied, and limits
Who: Mice with chemical (alkali) burns to the cornea, treated with full-length thymosin beta-4 drops or salt solution; group sizes are not given in the abstract.
Treated corneas regrew their surface layer faster at every time point and had fewer inflammatory white blood cells at 7 days than controls. Signals for several inflammation-related genes were lower.
Read with care: Mice, full-length protein, drops on the eye. This line of work led to the human eye-drop trials, which had mixed results.
- Animal study1999
Thymosin beta4 accelerates wound healing.
Thymosin beta-4 increased regrowth of the skin surface by 42% over saline at 4 days and by up to 61% at 7 days.
Full finding, who was studied, and limits
Who: Rats with full-thickness skin wounds, treated with full-length thymosin beta-4; group sizes are not given in the abstract.
Thymosin beta-4 increased regrowth of the skin surface by 42% over saline at 4 days and by up to 61% at 7 days. Treated wounds also contracted at least 11% more by day 7, with more collagen and new blood vessels.
Read with care: Rats, healthy skin, full-length protein. Not the TB-500 fragment and not people.
Journal of Investigative Dermatology · pubmed.ncbi.nlm.nih.gov
- Cell study2024
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.
The authors wrote that the biological effects of TB-500 itself had not been documented.
Full finding, who was studied, and limits
Who: Human serum and enzyme preparations, rats given TB-500 (urine analysed), and skin cells (fibroblasts) in a dish. Korea Institute of Science and Technology doping control centre.
The authors wrote that the biological effects of TB-500 itself had not been documented. In their cell tests, TB-500 and its breakdown products were not toxic to the cells, but only one breakdown product (Ac-LKKTE) significantly helped close a scratch wound compared with control. TB-500 itself did not. They suggested that healing activity attributed to TB-500 may come from that breakdown product.
Read with care: A scratch test in a dish, at one concentration. It does not show what happens in an animal or a person.
- Cell study2012
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.
Using high-resolution mass spectrometry (a method that weighs molecules very precisely), the lab identified the content of the TB-500 product as the acetyl-capped 17-23 fragment of human thymosin beta-4, Ac-LKKTETQ.
Full finding, who was studied, and limits
Who: Not a cell or animal study: a laboratory chemical analysis of a TB-500 product by the Ghent University doping control laboratory.
Using high-resolution mass spectrometry (a method that weighs molecules very precisely), the lab identified the content of the TB-500 product as the acetyl-capped 17-23 fragment of human thymosin beta-4, Ac-LKKTETQ. The team then made the same peptide themselves to confirm the match and proposed a way to detect it in blood and urine.
Read with care: Shows what that product contained in 2012. It says nothing about whether the peptide works or is safe, and it cannot tell you what any vial sold today contains.
Safety findings
- TB-500 fragment: FDA's 2026 review found no human exposure data, no clinical studies, and no animal toxicity studies of any kind (short-term, repeat-dose, genetic, reproductive or cancer). FDA concluded that the safety risks of use in people are unknown. Source: fda.gov
- TB-500 fragment: FDA's search of its adverse event database through March 2025 found no reports, and FDA cautioned that a lack of reports does not show a substance is safe. Two complaint-system reports mentioned a TB-500 and BPC-157 blend but contained no safety assessment. Source: fda.gov
- TB-500 fragment: FDA's stated concern is immunogenicity (the body mounting an immune reaction to the peptide), which could be made more likely by clumping of the peptide and by peptide-related impurities, especially in injected products. FDA also noted that publicly available lab reports for TB-500 did not test for impurities, clumps or bacterial toxins. Source: fda.gov
- Full-length thymosin beta-4, injected: in 40 healthy volunteers given it into a vein for up to 14 days, adverse events were infrequent and mild or moderate, with no serious adverse events. A separate study of a recombinant version in healthy Chinese volunteers (54 single-dose, 30 given it daily for 10 days) also reported only mild to moderate adverse events and no serious ones; three of its authors were employees of the sponsor. Source: pubmed.ncbi.nlm.nih.gov
3 more safety findings
- Full-length thymosin beta-4, eye drops: in the 700-person ARISE-3 trial no serious adverse events were recorded in either group; other adverse events were recorded in 13% of the drug group and 9% of the placebo group over 14 days. Source: clinicaltrials.gov
- Theoretical concern, not shown in people: thymosin beta-4 promotes cell movement and blood vessel growth, and mouse melanoma cells engineered to overproduce it formed larger tumours and more lung nodules. No human data show that thymosin beta-4 or TB-500 causes or speeds cancer, and no long-term human safety data exist to rule it out. Source: pubmed.ncbi.nlm.nih.gov
- No long-term human safety data were found for either substance. The longest controlled exposures found were 14 days (injection), 28 days (eye drops) and 84 days (skin gel), all with full-length thymosin beta-4. Source: clinicaltrials.gov
Rules and status
Not approved. Neither thymosin beta-4 nor the TB-500 fragment is an FDA-approved medicine, and as of November 2026 TB-500 is not on the list of substances that pharmacies may lawfully use for compounding.
The full history, with dates
What is formally in effect: (1) No approval. FDA's May 2026 briefing document states TB-500 is not a component of any FDA-approved drug. (2) Category 2 history. FDA placed 'Thymosin beta-4, fragment (LKKTETQ)' in Category 2 of its interim compounding policy, the group that raises significant safety risks (HHS's policy, Appendix B, gives the period as 29 September 2023 to 22 April 2026; the FDA pages opened confirm the placement but do not print the dates). FDA's stated reasons: possible immune reactions linked to clumping and peptide-related impurities, no human exposure data, and a lack of information on whether it would cause harm in people. (3) Removal in April 2026. FDA's safety-risks page, current as of 22 April 2026, now lists it under substances 'nominated but withdrawn', meaning the company that nominated it withdrew the nomination. Removal for that reason is not a finding that it is safe. FDA's category list updated 14 May 2026 shows it in neither Category 1 nor Category 2, so it was not moved 'back to Category 1'. (4) FDA review. FDA chose to evaluate TB-500 anyway. Its briefing document dated 15 May 2026 proposed NOT adding TB-500 (free base or acetate) to the compounding list, citing poor chemical characterisation, no evidence of effectiveness, and no human safety data. (5) HHS notice. On 30 October 2026 the Department of Health and Human Services published a Federal Register notice (91 FR 68526) announcing a draft 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances'. The notice says HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding with the listed peptides while rulemaking proceeds. It also says the policy is not binding, can be revisited, that compounded drugs are not FDA-approved, and that the compounding list itself is still to be developed through rulemaking. The comment period closed 13 November 2026. Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Appendix B limits the policy to TB-500 acetate in subcutaneous or intramuscular injectable dosage forms compounded from an ingredient with a certificate of analysis meeting the policy's ten conditions, which include a patient-specific prescription, a single active ingredient, a certificate from an FDA-registered manufacturer and reporting of serious side effects to the FDA. HHS gives three reasons for including TB-500: lot-specific certificates from FDA-registered manufacturers now supply the identification, assay, impurity, endotoxin, microbial and residual-solvent results the FDA found missing; historical use is now documented, where the FDA could not identify any pharmacy compounding TB-500; and the FDA's safety concerns are 'inferential rather than observed', the parent protein has a controlled human safety record across several routes, and the fragment is rapidly truncated in human serum. HHS states that neither the Category 2 placement nor its removal changed TB-500's status under section 503A, and that the advisory committee voted in favour of both forms. What is announced or reported but not formally established here: (a) Press and law-firm reports say the HHS Secretary said in a podcast interview on 27 February 2026 that peptides would be moved out of Category 2; that was not a formal HHS or FDA publication and no primary record of it was opened. (b) News reports say FDA's advisory committee voted 8 to 6, with 1 abstention, on 23 July 2026 in favour of adding TB-500 to the compounding list; the vote is advisory, HHS's policy says only that the committee voted in favour, and FDA's meeting page (last updated 6 August 2026) had posted no minutes or vote record. No proposed or final rule adding TB-500 to the 503A list was found. Placement in or out of an interim category has never changed the fact that TB-500 is unapproved.
Source: fda.gov (source dated 2026-05-14)
In sport: Prohibited at all times, in and out of competition. TB-500 is named in class S2 (Peptide hormones, growth factors, related substances, and mimetics), section S2.3 'Growth factors and growth factor modulators', which lists 'Thymosin-ß4 and its derivatives e.g. TB-500'. The wording is the same in the 2026 List (in force from 1 January 2026) and the 2027 List (published 21 September 2026, in force from 1 January 2027). The 2026 List states that all substances in S2 are non-Specified Substances. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| TB-500 is thymosin beta-4. | They are different molecules. Lab analysis in 2012 found TB-500 products contained a capped 7-amino-acid fragment, not the 43-amino-acid protein. FDA states that thymosin beta-4 and TB-500 are not the same substance, and that different substances have been sold under the TB-500 name. Source: fda.gov |
| TB-500 heals tendon, muscle and ligament injuries. | FDA's 2026 literature search found no study in which TB-500 was given to people for any condition, and no animal study testing whether TB-500 itself promotes wound healing. One small rat tendon study using a product sold as TB-500 was published in July 2026, after that search; it tested 4 tendons per group and did not check what the product contained. The human trials that exist used the full protein as eye drops or skin gel, not for tendons, muscles or joints. Source: fda.gov |
| The fragment is the active part of thymosin beta-4, so it works the same way. | A 2003 mouse study found an uncapped version of the fragment helped wounds in aged mice. But a 2024 cell study found TB-500 itself did not speed scratch-wound closure, while one of its breakdown products did. Other effects of thymosin beta-4 have been linked to parts of the protein the fragment does not contain. Source: pubmed.ncbi.nlm.nih.gov |
| Thymosin beta-4 is clinically proven to speed wound healing. | In three phase 2 skin-gel trials, the share of patients whose wounds healed was about the same with thymosin beta-4 and placebo (for example 12 of 55 versus 4 of 17 in venous ulcers). In the epidermolysis bullosa trial the placebo group did better (5 of 8 healed versus 8 of 22). A 2012 review argued that healing came sooner in the patients who did heal. No phase 3 wound trial has confirmed a benefit. Source: clinicaltrials.gov |
| Thymosin beta-4 eye drops were shown to work for dry eye. | A 72-person phase 2 trial missed both of its main goals. The two largest trials, with 601 and 700 people, posted near-identical results for drug and placebo on their main measures. The drops have not been approved. Source: clinicaltrials.gov |
| It repairs the heart after a heart attack. | This comes from mouse studies. A 2004 study reported better heart function in treated mice. A 2012 study found that treatment after a heart attack did not turn outer-layer heart cells into new heart muscle. In people, a 2025 randomised trial of the full-length protein (not the TB-500 fragment) in 96 heart-attack patients found no overall difference in the area of dead heart muscle; a smaller area in the 43 patients first treated within 8 hours is a subgroup result that needs confirming. Source: pubmed.ncbi.nlm.nih.gov |
| It is natural, so it is safe. | The full protein is natural, but the TB-500 fragment with its acetyl cap is a synthetic molecule. FDA found no toxicity studies and no human safety data for it. Safety data for the full protein in people cover at most 14 days of injection in 40 healthy volunteers. Source: fda.gov |
| The FDA legalised or approved TB-500 in 2026. | No. It was removed from FDA's Category 2 list in April 2026 because its nomination was withdrawn, not because FDA judged it safe. FDA staff recommended against adding it to the compounding list in May 2026. An October 2026 HHS notice describes a draft, non-binding enforcement policy for pharmacy compounding of certain peptides. None of this is an approval, and none of it applies to products sold online for research. Source: govinfo.gov |
What a genuine lab report should show
- The report should say exactly which substance was tested. 'TB-500' alone is not enough: it should name the sequence (Ac-LKKTETQ for the fragment, or the full 43-amino-acid thymosin beta-4) because both have been sold under similar names.
- Identity by mass spectrometry should match the expected molecular weight for the stated substance: about 889.0 g/mol for the TB-500 fragment (single-isotope mass about 888.49), or about 4963 g/mol for full-length thymosin beta-4. A result near one figure on a product labelled as the other means the label is wrong.
- The report should state whether the material is the free base or the acetate salt. FDA lists these as different substances (889.01 and 949.1 g/mol) and found suppliers using the same CAS number for both.
- Purity by HPLC (a method that separates a sample into its components), with the percentage of the largest single impurity and of total impurities, not just a headline purity figure.
- FDA noted that the lab reports it found for TB-500 covered only appearance, identity and purity. A fuller report would also show how much peptide is actually in the vial (assay or net peptide content), a test for bacterial endotoxins, and a check for aggregates (clumped peptide). FDA flagged the absence of these as a gap.
- A lot or batch number that matches the vial, the name of the testing laboratory, and the test date, so the report can be traced to the product in hand.
What is not known
- Whether the capped fragment sold as TB-500 has any healing effect in a living animal or a person. FDA found no in-vivo study of TB-500 itself for wound healing, and one cell study found the parent fragment inactive.
- What a given product labelled TB-500 actually contains. The 2012 analyses found the 7-amino-acid fragment; FDA and a 2025 doping-control paper both note that other substances, including full-length thymosin beta-4, are sold or advertised under the same or similar names. No systematic survey of current products was found.
- Whether the ClinicalTrials.gov record NCT07487363 (a phase 1/2 trial of the TB-500 fragment, sponsor listed as 'Hudson Biotech', one site in Shenzhen, China) describes a real, running trial. Its description says dose levels are 'not provided in this public example', which is unusual wording, and ClinicalTrials.gov does not verify sponsor-supplied information.
- Whether the October 2026 HHS enforcement discretion policy has been finalised. The Federal Register notice calls it both 'draft' and 'interim', and its comment period closed on 13 November 2026.
- The official record of the 23 July 2026 FDA advisory committee vote on TB-500. HHS states the committee voted in favour of both forms, and news reports give 8 to 6 with 1 abstention; no FDA minutes were found.
- Results of the SEER-2 eye-drop trial (70 patients, completed July 2026) and of a completed phase 2 heart-attack trial of recombinant thymosin beta-4 in China (NCT05485818). Neither had results posted on ClinicalTrials.gov when checked. A second such trial (NCT05984134) was published in a journal in 2025 (96 patients), though its registry record still shows no results and lists 90 enrolled.
- Long-term safety, including whether a peptide that promotes cell movement and blood vessel growth affects cancer risk. This remains a theoretical concern with no human data either way.
Sources
All 53 sources
- FDA briefing document on TB-500 for the Pharmacy Compounding Advisory Committee, dated 15 May 2026 (meeting 23-24 July 2026). fda.gov
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (current as of 22 April 2026). fda.gov
- FDA: Bulk drug substances nominated for use in compounding under section 503A, category list (updated 14 May 2026). fda.gov
- FDA: Bulk drug substances used in compounding under section 503A (category definitions; current as of 14 May 2026). fda.gov
- FDA advisory committee calendar: 23-24 July 2026 Pharmacy Compounding Advisory Committee meeting (current as of 6 August 2026). fda.gov
- FDA introduction briefing document for the July 2026 advisory committee meeting. fda.gov
- Federal Register, 30 October 2026 (91 FR 68526): HHS notice of availability, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. govinfo.gov
- Regulations.gov docket HHS-OASH-2026-0496 (comment period ended 13 November 2026). regulations.gov
- PubChem CID 62707662: TB-500 fragment (Ac-LKKTETQ). pubchem.ncbi.nlm.nih.gov
- PubChem CID 16132341: thymosin beta-4 (Timbetasin). pubchem.ncbi.nlm.nih.gov
- UniProt P62328: thymosin beta-4, human (TMSB4X). uniprot.org
- Esposito 2012: identification of Ac-LKKTETQ in TB-500. pubmed.ncbi.nlm.nih.gov
- Ho 2012: doping control analysis of TB-500 in horses. pubmed.ncbi.nlm.nih.gov
- Delcourt 2025: equine doping controls of thymosin β4 (notes online products claiming to contain the fragment or the full protein). pubmed.ncbi.nlm.nih.gov
- Rahaman 2024: TB-500 metabolites and wound-healing activity in cells. pubmed.ncbi.nlm.nih.gov
- Low 1981: complete amino acid sequence of bovine thymosin beta 4. pubmed.ncbi.nlm.nih.gov
- Safer 1991: thymosin beta 4 and the actin-sequestering peptide Fx are indistinguishable. pubmed.ncbi.nlm.nih.gov
- Sosne 2010: biological activities of thymosin beta4 defined by active sites in short peptide sequences (review). pubmed.ncbi.nlm.nih.gov
- Goldstein 2005: thymosin beta4, actin-sequestering protein moonlights to repair injured tissues (review). pubmed.ncbi.nlm.nih.gov
- Malinda 1999: thymosin beta4 accelerates wound healing (rats). pubmed.ncbi.nlm.nih.gov
- Philp 2003: thymosin beta 4 and LKKTETQ in diabetic and aged mice. pubmed.ncbi.nlm.nih.gov
- Biçer 2026: BPC-157 and TB-500 in Achilles tendon healing (rats). pubmed.ncbi.nlm.nih.gov
- Sosne 2002: thymosin beta 4 and corneal healing after alkali injury (mice). pubmed.ncbi.nlm.nih.gov
- Bock-Marquette 2004: thymosin beta4 and cardiac repair (mice). pubmed.ncbi.nlm.nih.gov
- Smart 2007: thymosin beta4 and adult epicardial progenitor mobilization (mice). pubmed.ncbi.nlm.nih.gov
- Zhou 2012: thymosin beta 4 after myocardial infarction does not reprogram epicardial cells. pubmed.ncbi.nlm.nih.gov
- Cha 2003: role of thymosin beta4 in tumor metastasis and angiogenesis. pubmed.ncbi.nlm.nih.gov
- Ruff 2010: intravenous thymosin beta4 in healthy volunteers (phase 1). pubmed.ncbi.nlm.nih.gov
- Wang 2021: recombinant human thymosin β4 in healthy Chinese volunteers (phase 1). pubmed.ncbi.nlm.nih.gov
- Guarnera 2010: thymosin treatment of venous ulcers (phase 2). pubmed.ncbi.nlm.nih.gov
- Treadwell 2012: review of thymosin β4 dermal healing in animals and patients. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov NCT00832091: thymosin beta 4 in venous stasis ulcers (results posted). clinicaltrials.gov
- ClinicalTrials.gov NCT00382174: thymosin beta 4 in pressure ulcers (results posted). clinicaltrials.gov
- ClinicalTrials.gov NCT00311766: thymosin beta 4 in epidermolysis bullosa (terminated; results posted). clinicaltrials.gov
- ClinicalTrials.gov NCT03578029: RGN-137 gel in epidermolysis bullosa (terminated, 4 enrolled). clinicaltrials.gov
- Sosne and Ousler 2015: thymosin beta 4 eye drops for dry eye, phase 2 (72 people). pubmed.ncbi.nlm.nih.gov
- Sosne 2015: thymosin β4 in severe dry eye, phase 2 (9 patients). pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov NCT02597803: ARISE-1 (317 people; no results posted). clinicaltrials.gov
- ClinicalTrials.gov NCT02974907: ARISE-2 (601 people; results posted). clinicaltrials.gov
- ClinicalTrials.gov NCT03937882: ARISE-3 (700 people; results posted). clinicaltrials.gov
- Sosne 2022: RGN-259 in neurotrophic keratopathy, SEER-1 (18 patients). pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov NCT02600429: SEER-1 (terminated; results posted). clinicaltrials.gov
- ClinicalTrials.gov NCT05555589: SEER-2 (70 patients; completed July 2026; no results posted). clinicaltrials.gov
- Cochrane review 2025: medical and surgical interventions for neurotrophic keratopathy. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov NCT01311518: injectable thymosin beta 4 for acute myocardial infarction (withdrawn, 0 enrolled). clinicaltrials.gov
- ClinicalTrials.gov NCT07487363: registered phase 1/2 trial of the TB-500 fragment (recruiting; no results). clinicaltrials.gov
- WADA 2026 Prohibited List (S2.3 names thymosin-ß4 and its derivatives e.g. TB-500). wada-ama.org
- WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
- Zhang 2025: recombinant human thymosin beta 4 in mice and in a 96-patient heart attack trial (NCT05984134). pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov NCT05984134: recombinant thymosin beta 4 in acute myocardial infarction (completed 2023; no results posted). clinicaltrials.gov
- Lu 2025: TB500 (LKKTETQ) peptide hydrogel for corneal injury. pubmed.ncbi.nlm.nih.gov
- Jeong 2026: thymosin beta 4 overexpression and liver injury after repeated irradiation (mice). pubmed.ncbi.nlm.nih.gov
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.